Open AccessTargeting the Difficult-to-Drug CD71 and MYCN with Gambogic Acid and Vorinostat in a Class of Neuroblastomas
Author(s) -
Kausik Bishayee,
Khadija Habib,
Ali Sadra,
SungOh Huh
Publication year - 2019
Publication title -
cellular physiology and biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.486
H-Index - 87
eISSN - 1421-9778
pISSN - 1015-8987
DOI - 10.33594/000000134
Subject(s) - vorinostat , neuroblastoma , transferrin receptor , cancer research , gambogic acid , gene silencing , biology , viability assay , transfection , microarray analysis techniques , pharmacology , transferrin , histone deacetylase , apoptosis , cell culture , gene expression , biochemistry , gene , genetics , histone
Although neuroblastoma is a heterogeneous cancer, a substantial portion overexpresses CD71 (transferrin receptor 1) and MYCN. This study provides a mechanistically driven rationale for a combination therapy targeting neuroblastomas that doubly overexpress or have amplified CD71 and MYCN. For this subset, CD71 was targeted by its natural ligand, gambogic acid (GA), and MYCN was targeted with an HDAC inhibitor, vorinostat. A combination of GA and vorinostat was then tested for efficacy in cancer and non-cancer cells.